Sulfoquinovosyl acylpropanediol (SQAP; a synthetic derivative of the sulfoglycolipid
natural product sulfoquinovosyl
acylglycerol, SQAG), has anti-
tumor and radiosensitizing activities in
tumor xenograft mouse models. Here, we have studied the PARP inhibitory activity of SQAP and synthetic lethality in BRCA2-deficient cells. In initial screening studies with
DNA repair-deficient Chinese hamster ovary cells, homologous recombination repair-deficient cell lines showed increased sensitivity to SQAP, compared to wild-type cells or other
DNA repair-deficient mutants. Chinese hamster lung V79 cells and the derivative cell lines V-C8 (BRCA2-deficient) and V-C8 + BRCA2 gene corrections were used to test the role of BRCA2 in SQAP cytotoxicity. The findings were confirmed in studies of the human
colon cancer cell lines DLD-1 and its BRCA2-knockout derivative. SQAP inhibited the
enzymes poly(ADP-ribose) polymerase (PARP) and
poly(ADP-ribose) glycohydrolase (PARG). SQAP pretreatment decreased H2O2induced
poly(ADP-ribose) formation in V79 cells. SQAP caused
DNA double-strand breaks and
chromosome aberrations in V79 BRCA2-mutated cells but did not affect cells in the G2 phase. We have demonstrated that SQAP induces synthetic lethality in BRCA2-deficient Chinese hamster-derived cells via its effects on
poly(ADP-ribose) metabolism, motivating further examination of its therapeutic potential, especially against
tumors that are deficient in homologous recombination repair due to mutations in BRCA2 or other genes.